FIG. 9.

DZNep treatment restores expression levels of RAD51 and BRCA1 through epigenetic mark H3K27me3. A) Location of regions analyzed by ChIP/PCR along human RAD51 and BRCA1 promoters. The position of the transcriptional start site was designated as +1. Short horizontal lines indicate the regions analyzed by ChIP/PCR. B) ChIP/quantitative PCR was performed with anti-H3K27me3 antibody in the RAD51 promoter region in fibroid primary cells in the presence or absence of DZNep. C) ChIP/quantitative PCR was performed with anti-H3K4me3 antibody in the RAD51 promoter region in fibroid primary cells in the presence or absence of DZNep. D) ChIP/quantitative PCR was performed to determine the enrichment of H3K27me3 in the distal and proximal promoter regions of BRCA1 in the presence or absence of DZNep. E) ChIP/quantitative PCR was performed to determine the enrichment of H3K4me3 in the distal and proximal promoter regions of BRCA1 in the presence or absence of DZNep. *P < 0.05 compared with the control.